"Designing Growth Strategies is in our DNA"

Biosimilars Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Filgrastim & Peg-filgrastim, Monoclonal Antibodies, and Others), By Disease Indication (Cancer, Autoimmune Diseases {Arthritis, Psoriasis, and Others}, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: March 09, 2026 | Format: PDF | Report ID: FBI108928

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Market Scope
    2. Market Segmentation
    3. Market Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
    2. New Product Launches, By Key Players
    3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
    4. Regulatory Scenario, Key Countries/Regions
    5. Pipeline Analysis, By Key Players
    6. Impact of COVID-19 on the Market
  5. Global Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Other Facilities
    4. Market Analysis, Insights and Forecast – By Country
      1. U.S.
        1. By Drug Class
      2. Canada
        1. By Drug Class
  7. Europe Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. U.K.
        1. By Drug Class
      2. Germany
        1. By Drug Class
      3. France
        1. By Drug Class
      4. Italy
        1. By Drug Class
      5. Spain
        1. By Drug Class
      6. Scandinavia
        1. By Drug Class
      7. Rest of Europe
        1. By Drug Class
  8. Asia Pacific Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Disease Indication
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. China
        1. By Drug Class
      2. India
        1. By Drug Class
      3. Japan
        1. By Drug Class
      4. Australia
        1. By Drug Class
      5. Southeast Asia
        1. By Drug Class
      6. Rest of Asia Pacific
        1. By Drug Class
  9. Latin America Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil
        1. By Drug Class
      2. Mexico
        1. By Drug Class
      3. Rest of Latin America
        1. By Drug Class
  10. Middle East & Africa Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. GCC
        1. By Drug Class
      2. South Africa
        1. By Drug Class
      3. Rest of Middle East & Africa
        1. By Drug Class
  11. Competitive Analysis
    1. Global Market Share Analysis (2025)
    2. Company Profiles
      1. Celltrion Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Pfizer Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Novartis AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Amgen Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Biocon
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Biogen
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Coherus BioSciences
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Samsung Bioepis
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Shanghai Henlius Biotech, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
  1. Introduction
    1. Market Scope
    2. Market Segmentation
    3. Market Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
    2. New Product Launches, By Key Players
    3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
    4. Regulatory Scenario, Key Countries/Regions
    5. Pipeline Analysis, By Key Players
    6. Impact of COVID-19 on the Market
  5. Global Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Other Facilities
    4. Market Analysis, Insights and Forecast – By Country
      1. U.S.
        1. By Drug Class
      2. Canada
        1. By Drug Class
  7. Europe Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. U.K.
        1. By Drug Class
      2. Germany
        1. By Drug Class
      3. France
        1. By Drug Class
      4. Italy
        1. By Drug Class
      5. Spain
        1. By Drug Class
      6. Scandinavia
        1. By Drug Class
      7. Rest of Europe
        1. By Drug Class
  8. Asia Pacific Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Disease Indication
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. China
        1. By Drug Class
      2. India
        1. By Drug Class
      3. Japan
        1. By Drug Class
      4. Australia
        1. By Drug Class
      5. Southeast Asia
        1. By Drug Class
      6. Rest of Asia Pacific
        1. By Drug Class
  9. Latin America Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil
        1. By Drug Class
      2. Mexico
        1. By Drug Class
      3. Rest of Latin America
        1. By Drug Class
  10. Middle East & Africa Biosimilars Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. GCC
        1. By Drug Class
      2. South Africa
        1. By Drug Class
      3. Rest of Middle East & Africa
        1. By Drug Class
  11. Competitive Analysis
    1. Global Market Share Analysis (2025)
    2. Company Profiles
      1. Celltrion Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Pfizer Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Novartis AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Amgen Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Biocon
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Biogen
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Coherus BioSciences
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Samsung Bioepis
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Shanghai Henlius Biotech, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 01: Global Biosimilars Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 02: Global Biosimilars Market Value Share (%), by Drug Class, 2025 & 2034

Figure 03: Global Biosimilars Market Value Share (%), by Disease Indication, 2025 & 2034

Figure 04: Global Biosimilars Market Value Share (%), by Distribution Channel, 2025 & 2034

Figure 05: Global Biosimilars Market Value (USD billion), by Region, 2025 & 2034

Figure 06: North America Biosimilars Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 07: North America Biosimilars Market Value Share (%), By Drug Class, 2025

Figure 08: North America Biosimilars Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 09: North America Biosimilars Market Value Share (%), By Disease Indication, 2025

Figure 10: North America Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 11: North America Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 12: North America Biosimilars Market Value (USD billion), By Country, 2025 & 2034

Figure 13: North America Biosimilars Market Value Share (%), By Country, 2025

Figure 14: Europe Biosimilars Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 15: Europe Biosimilars Market Value Share (%), By Drug Class, 2025

Figure 16: Europe Biosimilars Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 17: Europe Biosimilars Market Value Share (%), By Disease Indication, 2025

Figure 18: Europe Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 19: Europe Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 20: Europe Biosimilars Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 21: Europe Biosimilars Market Value Share (%), By Country/ Sub-region, 2025

Figure 22: Asia Pacific Biosimilars Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 23: Asia Pacific Biosimilars Market Value Share (%), By Drug Class, 2025

Figure 24: Asia Pacific Biosimilars Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 25: Asia Pacific Biosimilars Market Value Share (%), By Disease Indication, 2025

Figure 26: Asia Pacific Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 27: Asia Pacific Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 28: Asia Pacific Biosimilars Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 29: Asia Pacific Biosimilars Market Value Share (%), By Country/ Sub-region, 2025

Figure 30: Latin America Biosimilars Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 31: Latin America Biosimilars Market Value Share (%), By Drug Class, 2025

Figure 32: Latin America Biosimilars Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 33: Latin America Biosimilars Market Value Share (%), By Disease Indication, 2025

Figure 34: Latin America Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 35: Latin America Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 36: Latin America Biosimilars Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 37: Latin America Biosimilars Market Value Share (%), By Country/ Sub-region, 2025

Figure 38: Middle East & Africa Biosimilars Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 39: Middle East & Africa Biosimilars Market Value Share (%), By Drug Class, 2025

Figure 40: Middle East & Africa Biosimilars Market Value (USD billion), By Disease Indication, 2025 & 2034

Figure 41: Middle East & Africa Biosimilars Market Value Share (%), By Disease Indication, 2025

Figure 42: Middle East & Africa Biosimilars Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 43: Middle East & Africa Biosimilars Market Value Share (%), by Distribution Channel, 2025

Figure 44: Middle East & Africa Biosimilars Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 45: Middle East & Africa Biosimilars Market Value Share (%), By Country/ Sub-region, 2025

Figure 46: Global Biosimilars Market Share (%), By Company, 2025

Table 01: Global Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 02: Global Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 03: Global Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 04: Global Biosimilars Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 05: North America Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 06: North America Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 07: North America Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 08: North America Biosimilars Market Revenue (USD billion) Forecast, By Country, 2021-2034

Table 09: U.S. Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 10: Canada Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 11: Europe Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 12: Europe Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 13: Europe Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 14: Europe Biosimilars Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 15: U.K. Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 16: Germany Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 17: France Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 18: Italy Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 19: Spain Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 20: Scandinavia Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 21: Rest of Europe Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 22: Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 23: Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 24: Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 25: Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 26: China Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 27: India Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 28: Japan Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 29: Australia Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 30: Southeast Asia Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 31: Rest of Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 32: Latin America Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 33: Latin America Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 34: Latin America Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 35: Latin America Biosimilars Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 36: Brazil Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 37: Mexico Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 38: Rest of Latin America Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 39: Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 40: Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034

Table 41: Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 42: Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 43: GCC Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 44: South Africa Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Table 45: Rest of Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034

Biosimilars Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 150
Download Free Sample

    man icon
    Mail icon
    Captcha refresh

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Get 20% Free Customization On This Report
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports